SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (609)2/11/1998 4:24:00 PM
From: Vector1  Respond to of 1686
 
Rick,
IDEC has not been shy about rolling out clinicals arguably in viation of others patents. The imaging phase of Y2B8 administration in my opinion infringes on Coulters patent. The Coulter people (surprise surprise) expressed the same view to me at the HQ conference. It may very well be one of the main reasons Genentec dropped Y2B8.
V1



To: scaram(o)uche who wrote (609)2/12/1998 8:24:00 PM
From: Harold Engstrom  Read Replies (2) | Respond to of 1686
 
Richard, can you help me understand what having composition of matter rights entitles Biogen to (in theory) and what innovation seems to have occurred at IDEC and what that innovation does to Biogen's exclusivity with regard to 5C8?